Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0431/ONO-5435 Phase III add-on study to rapid-acting insulin secretagogues in type 2 diabetes
jRCT2080221627Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin add-on with Placebo add-on (2 arms). Primary endpoints: Safety and tolerability over 52 weeks and Glycemic efficacy over 52 weeks. Started Oct 2011; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221627.